Physician profile
Michael Esantsi
NPI 1447260518
$6,912.02
in general payments reported to CMS, 2019-2025
38 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $538 · 2021: $574 · 2022: $1,368 · 2023: $1,127 · 2024: $1,164 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,527 · Travel and Lodging: $361 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,527.17 |
| Travel and Lodging | $361.40 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,408.50 | 2019-2025 | Ozempic, Rybelsus, Tresiba |
| Bayer Healthcare Pharmaceuticals INC. | $971.84 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $841.31 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Stryker Corporation | $530.32 | 2025 | Mako |
| Amgen INC. | $384.61 | 2019-2025 | Krystexxa, Otezla, Repatha |
| Mylan Specialty L.P. | $326.08 | 2020-2024 | Yupelri |
| Lilly USA, LLC | $316.21 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Kowa Pharmaceuticals America, INC. | $233.60 | 2022-2025 | Livalo, Seglentis, Zoryve |
| Currax Pharmaceuticals LLC | $166.65 | 2021-2024 | Contrave, Nexletol, Nexlizet |
| Pfizer INC. | $160.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $153.27 | 2019-2024 | Xarelto |
| Azurity Pharmaceuticals, INC. | $142.43 | 2023-2024 | Horizant, Horizant |
| Merck Sharp & Dohme LLC | $137.68 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $99.92 | 2023-2025 | Veozah |
| Exact Sciences Corporation | $92.35 | 2024-2025 | Cologuard Collection Kit |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Esantsi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.